A J Phipps-Green1, M E Merriman1, R Topless1, S Altaf1, G W Montgomery2, C Franklin3, G T Jones4, A M van Rij4, D White5, L K Stamp6, N Dalbeth3, T R Merriman1. 1. Department of Biochemistry, University of Otago, Dunedin, New Zealand. 2. Queensland Institute of Medical Research, Brisbane, Queensland, Australia. 3. Department of Medicine, University of Auckland, Auckland, New Zealand. 4. Department of Medicine, University of Otago, Dunedin, New Zealand. 5. Waikato District Health Board, Hamilton, New Zealand. 6. Department of Medicine, University of Otago, Christchurch, New Zealand.
Abstract
OBJECTIVES: Twenty-eight genetic loci are associated with serum urate levels in Europeans. Evidence for association with gout at most loci is absent, equivocal or not replicated. Our aim was to test the loci for association with gout meeting the American College of Rheumatology gout classification criteria in New Zealand European and Polynesian case-control sample sets. METHODS: 648 European cases and 1550 controls, and 888 Polynesian (Ma¯ori and Pacific) cases and 1095 controls were genotyped. Association with gout was tested by logistic regression adjusting for age and sex. Power was adequate (>0.7) to detect effects of OR>1.3. RESULTS: We focused on 24 loci without previous consistent evidence for association with gout. In Europeans, we detected association at seven loci, one of which was the first report of association with gout (IGF1R). In Polynesian, association was detected at three loci. Meta-analysis revealed association at eight loci-two had not previously been associated with gout (PDZK1 and MAF). In participants with higher Polynesian ancestry, there was association in an opposing direction to Europeans at PRKAG2 and HLF (HLF is the first report of association with gout). There was obvious inconsistency of gout association at four loci (GCKR, INHBC, SLC22A11, SLC16A9) that display very similar effects on urate levels. CONCLUSIONS: We provide the first evidence for association with gout at four loci (IGF1R, PDZK1, MAF, HLF). Understanding why there is lack of correlation between urate and gout effect sizes will be important in understanding the aetiology of gout. Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://www.bmj.com/company/products-services/rights-and-licensing/
OBJECTIVES: Twenty-eight genetic loci are associated with serum urate levels in Europeans. Evidence for association with gout at most loci is absent, equivocal or not replicated. Our aim was to test the loci for association with gout meeting the American College of Rheumatology gout classification criteria in New Zealand European and Polynesian case-control sample sets. METHODS: 648 European cases and 1550 controls, and 888 Polynesian (Ma¯ori and Pacific) cases and 1095 controls were genotyped. Association with gout was tested by logistic regression adjusting for age and sex. Power was adequate (>0.7) to detect effects of OR>1.3. RESULTS: We focused on 24 loci without previous consistent evidence for association with gout. In Europeans, we detected association at seven loci, one of which was the first report of association with gout (IGF1R). In Polynesian, association was detected at three loci. Meta-analysis revealed association at eight loci-two had not previously been associated with gout (PDZK1 and MAF). In participants with higher Polynesian ancestry, there was association in an opposing direction to Europeans at PRKAG2 and HLF (HLF is the first report of association with gout). There was obvious inconsistency of gout association at four loci (GCKR, INHBC, SLC22A11, SLC16A9) that display very similar effects on urate levels. CONCLUSIONS: We provide the first evidence for association with gout at four loci (IGF1R, PDZK1, MAF, HLF). Understanding why there is lack of correlation between urate and gout effect sizes will be important in understanding the aetiology of gout. Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://www.bmj.com/company/products-services/rights-and-licensing/
Authors: Richard J Johnson; George L Bakris; Claudio Borghi; Michel B Chonchol; David Feldman; Miguel A Lanaspa; Tony R Merriman; Orson W Moe; David B Mount; Laura Gabriella Sanchez Lozada; Eli Stahl; Daniel E Weiner; Glenn M Chertow Journal: Am J Kidney Dis Date: 2018-02-27 Impact factor: 8.860
Authors: Richard J Reynolds; Ana I Vazquez; Vinodh Srinivasasainagendra; Yann C Klimentidis; S Louis Bridges; David B Allison; Jasvinder A Singh Journal: Rheumatol Int Date: 2015-10-01 Impact factor: 2.631
Authors: Callum Tanner; James Boocock; Eli A Stahl; Amanda Dobbyn; Asim K Mandal; Murray Cadzow; Amanda J Phipps-Green; Ruth K Topless; Jennie Harré Hindmarsh; Lisa K Stamp; Nicola Dalbeth; Hyon K Choi; David B Mount; Tony R Merriman Journal: Arthritis Rheumatol Date: 2017-05-31 Impact factor: 10.995
Authors: Mohanraj Krishnan; Tanya J Major; Ruth K Topless; Ofa Dewes; Lennex Yu; John M D Thompson; Lesley McCowan; Janak de Zoysa; Lisa K Stamp; Nicola Dalbeth; Jennie Harré Hindmarsh; Nuku Rapana; Ranjan Deka; Winston W H Eng; Daniel E Weeks; Ryan L Minster; Stephen T McGarvey; Satupa'itea Viali; Take Naseri; Muagututi'a Sefuiva Reupena; Phillip Wilcox; David Grattan; Peter R Shepherd; Andrew N Shelling; Rinki Murphy; Tony R Merriman Journal: Diabetologia Date: 2018-05-02 Impact factor: 10.122
Authors: Tahzeeb Fatima; Sara Altaf; Amanda Phipps-Green; Ruth Topless; Tanya J Flynn; Lisa K Stamp; Nicola Dalbeth; Tony R Merriman Journal: Rheumatol Int Date: 2015-09-26 Impact factor: 2.631